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Abstract
HD (Huntington’s disease) is caused by a polyQ (polyglutamine) expansion in the huntingtin protein, which
leads to protein misfolding and aggregation of this protein. Abnormal copper accumulation in the HD brain
was ﬁrst reported more than 15 years ago. Recent ﬁndings show that copper-regulatory genes are induced
during HD and copper binds to anN-terminal fragment of huntingtin, supporting the involvement of abnormal
copper metabolism in HD. We have demonstrated that in vitro copper accelerates the ﬁbrillization of an
N-terminal fragment of huntingtin with an expanded polyQ stretch (httExon1). As we found that copper also
increases polyQ aggregation and toxicity in mammalian cells expressing httExon1, we investigated further
whether overexpression of genes involved in copper metabolism, notably MTs (metallothioneins) known to
bind copper, protect against httExon1 toxicity. Using a yeastmodel of HD,we have shown that overexpression
of several genes involved in copper metabolism reduces polyQ-mediated toxicity. Overexpression of MT-3
in mammalian cells signiﬁcantly reduced polyQ aggregation and toxicity. We propose that copper-binding
and/or -chaperoning proteins, especially MTs, are potential therapeutic targets for HD.
Introduction
HD (Huntington’s disease) is a neurodegenerative disorder
caused by an abnormal polyQ (polyglutamine) expansion in
the 350 kDa protein htt (huntingtin). HD is associated with
intracellular aggregates (or inclusion bodies) and neuronal
loss, occurring predominantly in the striatum and cerebral
cortex. Post-translational modifications and cleavage of htt
occur in vivo, and the resulting N-terminal htt fragments
containing the polyQ stretch are prone to misfolding and
aggregation [1]. This misfolding and/or aggregation probably
leads to a toxic gain-of-function, although loss of normal
htt function, which has been implicated as a participant in
a variety of cellular functions, may also play a role during
disease. Many cellular dysfunctions have been identified that
could participate in the disease process, including impaired
transcription, mitochondrial abnormalities, dysregulation of
the cellular redox homoeostasis and defects in protein-
degradation pathways, axonal transport and synaptic func-
tion (for a recent review, see [2]).
Both iron and copper accumulate in the CNS (central
nervous system) of HD mouse models and in the HD brain
[3,4] and could play a role in the above-mentioned cellular
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alterations that occur in HD. Indeed, several previous find-
ings point to the importance of copper in HD. Clioquinol,
a copper/iron chelator, significantly delays neuropathology
in HD mice [5], and N-terminal htt binds copper both
in vitro and in vivo [4]. Htt has also been shown to reduce
copper(II) and increase aggregation of the full-length wild-
type (non-expanded) htt protein of mice [4]. The reduction
in copper and concomitant increase in oligomerization has
also been demonstrated for β-amyloid and is suggested to
play a role in the pathogenesis of Alzheimer’s disease [6,7].
Copper is crucial for electron-transfer reactions in a number
of enzymes involved in activities such as antioxidant defence
and neurotransmitter biosynthesis. Despite this essential
requirement for copper, an excess of this heavy metal is
toxic, primarily because of its reactivity with molecular
oxygenwhich leads to the formation of ROS (reactive oxygen
species). Therefore the transport and compartmentalization
of copper is highly regulated, involving copper transporters
and chaperones (see Table 1). By examining published gene
expression data from HD cell and mouse models and human
HD brain tissue, we found that copper-binding/chaperoning
proteins, includingMTs (metallothioneins),were consistently
up-regulated (Table 1). This could reflect a protective
response against increased copper and ROS, and/or a
disruption of copper homoeostasis more generally. This
observation led us to test whether overexpression of copper-
regulating genes in yeast and mammalian cell models of
HD reduce htt toxicity. Because oligomerization and the
production of amyloid-like structures of N-terminal htt has
been tightly linked to cellular toxicity [8–11], we have also
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Table 1 Yeast and mammalian homologues of copper-binding proteins
Altered expression in HD models and/or effects on toxicity in a yeast model of HD are indicated (data compiled from seven studies including ours).
IRE, iron-responsive element.
Expression changes in Effect on httEx1 toxicity in
Mammalian homologue HD models Function Yeast homologue yeast model
MT1/MT2 mRNA up-regulated
(5-fold) in PC12 cells,
Tet-On Q74 [21] and
in human HD brain
[44]
Metal donation to target
apometalloproteins
(particularly zinc-ﬁnger
proteins and enzymes),
metal detoxiﬁcation, and
antioxidant
Crs5
Cup1-2
Rescues
Rescues
MT3
CCS [copper chaperone for SOD
(superoxide dismutase)]
Transports copper to CuZn
SOD
Lys-7 Rescues
Atox1 (antioxidant protein 1) Delivers copper to
copper-binding domain
of MNK/WND. Protects
neurons against
oxidative stress and
serum starvation
Atx1 Rescues
Cox17 (cytochrome c oxidase
17)
Delivers copper to
cytochrome c oxidase in
mitochondria, required
for functional expression
of cytochrome c oxidase
Cox17
Cox23
Rescues
Rescues (not shown)
ATP7A (MNK) (Menkes’s
disease protein)
Copper-translocating P-type
ATPase. Delivers copper
to cuproenzymes in the
Golgi compartment and
efﬂuxes excess copper
Ccc2 Rescues (not shown)
ATP7B (WND) (Wilson’s
disease protein)
Protein up-regulated in
R6/2 mice [4]
Functions within the
secretory apparatus,
loading cytoplasmic
copper onto the plasma
ferroxidase
caeruloplasmin
(facilitates iron export)
Ceruloplasmin mRNA up-regulated in
striatal primary
neurons
(httN171Q82), R6/1,
R6/2 mice and
human HD brain
[44–47]
Copper storage, iron
metabolism
Fet3 Not tested
DMT1 (divalent metal
transporter 1) [Nramp2
(natural resistance-
associated macrophage
protein 2)]
Non-speciﬁc bivalent cation
transporter (import) for
iron (contains IRE) and
copper
Smf1, Smf2 and Smf3 Not tested
investigated whether copper modulates the formation of such
protein assemblies usingAFM (atomic forcemicroscopy) and
biochemical assays and tested whether increased expression
of copper-binding proteins reduces htt aggregation.
Protein puriﬁcation and AFM
pGEX-HD53/20Q plasmids were kindly provided by Paul
Muchowski (Gladstone Institute of Neurological Disease,
University of California, San Francisco, CA, U.S.A.)
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and httEx1-GST was prepared as described previously
[12,13]. The integrity of the protein was validated using
SDS/PAGE. The protein was dialysed in 20 mM Tris/HCl
(pH 8), 150 mM NaCl, 0.1 mM EDTA and 5% glycerol.
Freshly prepared protein samples were used for each
experiment performed at 4◦C. CuCl2 (10 μM) was added
before the addition of PreScission protease (2 units/100 μg
of protein) to 50 μMGST (glutathione transferase)–htt-Q20
or -Q53 to initiate GST cleavage. At 24 h after the addition
of PreScission protease and/or CuCl2, 5 μl (12 μg of pro-
tein) of the reaction mixture was spotted on to a freshly
cleaved mica disc, incubated for 2 min and then rinsed with
200 μl of ultrapure water and dried with compressed air.
The samples were imaged in air with a digital multimode
Nanoscope III AFM operating in tapping mode with an
uncoated silicon tip.
Cell culture, DNA transfection and
adenovirus infection
HeLa cells were grown in 4500 mg/ml DMEM
(Dulbecco’s modified Eagle’s medium) with 100 units/ml
penicillin/streptomycin, 2 mM L-glutamine, 1 mM sodium
pyruvate and 10% FBS (fetal bovine serum) at 37◦C under
10% CO2. For transfection, 150000 HeLa cells per well
were plated in six-well plates/35 mm dishes and exposed
to 2 μg of human MT3 DNA (SC123646; OriGene) and
4 μl of Lipofectamine per well for 5 h (24 h after seeding)
in serum-free medium, after which culture medium was
added. At 24 h later, cells were trypsinized and re-plated in
96-well plates. Alternatively, cells were treated with CuCl2
or clioquinol for 24 h in six-well plates before being re-plated
into 96-well plates. Before re-plating, equal numbers of
cells were infected in suspension at an MOI (multiplicity
of infection) of 10 with an adenovirus expressing httEx1
containing either 25 or 97 glutamine residues fused to
mRFP (monomeric red fluorescent protein) at the httEx1
C-terminus. Cells were then cultured for a further 48 h
in the presence or absence of CuCl2 or clioquinol where
appropriate, after which an MTS [3-(4,5-dimethylthiazol-
2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium] assay was performed following standard
protocols using a plate reader at a wavelength of 490 nm.
Cells were fixed subsequently for immunoblot analysis.
Overexpression of MT3 was verified by Western blotting.
Dot blot and Western blot analysis
Cell lysis, SDS/PAGE, preparation of samples for dot blots
and Western blots were performed as described previously
[14]. Dot blot samples, normalized for total protein content,
were filtered on a dot blot filtration unit through a cellulose
acetate membrane with a pore size of 0.2 μm that was pre-
equilibrated with 2% SDS. HttEx1 was detected using a
sheep anti-httEx1 antibody at a concentration of 1:6000
(S830, a gift from Gillian Bates, Kings College London,
London, U.K.) followed by a secondary HRP (horseradish
peroxidase)-conjugated anti-sheep antibody and enhanced
chemiluminescence detection. MT3 was detected on a
Western blot using an anti-mouse MT3 antibody, followed
by an HRP-conjugated secondary anti-mouse antibody and
enhanced chemiluminescence detection.
Overexpression of copper-modulating
genes in yeast
Yeast strains containing plasmids for the overexpression
of selected genes were obtained from the Yeast ORF
(open reading frame) Collection (Open Biosystems). The
relevant yeast strains were grown overnight in 96-well plates
containing 100 μl of selectivemedium supplementedwith 2%
glucose per well and transformed with either p425GALL-
htt25Q-GFP or p425GALL-htt103Q-GFP using a high-
throughput transformation method [15]. The constructs
p425GALL-htt25Q-GFP and p425GALL-htt103Q-GFP
were generated by amplifying the huntingtin constructs
from pYES2-htt25Q-GFP and pYES2-htt103Q-GFP [16]
and cloning them into the SpeI and XhoI sites of p425GALL
[17]. Both htt103Q and htt25Q are GAL (galactose)-
inducible, FLAG- and GFP (green fluorescent protein)-
tagged constructs encoding the first 17 amino acids of
htt fused to a polyQ tract. Transformants were grown
to stationary phase in selective medium containing 2%
glucose, serial diluted, and spotted on to selective medium
supplemented with either 2% glucose or 2% galactose and
2% raffinose. Plates were incubated at 30◦C for 3–5 days and
yeast strains were scored for growth.
Statistical analysis
Pairwise comparisons were conducted using a two-tailed
Student’s t test and 95% (*) or 99% (**) confidence
intervals were used for calculating significance. The number
of experiments performed for each result is indicated in the
Figure legends.
Results
We used an in vitro model of htt aggregation involving
purification of a GST fusion protein of exon 1 of htt (httEx1)
followed by cleavage of the GST tag, which induces a time-
dependent aggregation of httEx1 [8,18]. Cleavage of the GST
moiety from httEx1-Q20 did not lead to any detectable
aggregation, but imaging of samples of httEx1-Q53 by
AFM revealed amyloid-like fibrillar structures (Figure 1A).
Addition of 10 μM CuCl2 significantly accelerated the
production of httEx1 fibrillar structures (Figure 1A). An
increase in aggregation due to addition of CuCl2 to purified
httEx1-Q53 was also demonstrated using a filter trap assay,
which detects SDS-insoluble material produced by httEx1
(Figure 1B).
Owing to the observed effect of copper on aggregation
of httEx1 protein in vitro, we hypothesized that alterations
in copper metabolism would affect aggregation and toxicity
induced by expression of httEx1 in vivo. Therefore we tested
the ability of overexpression of several yeast genes known
to be involved in copper homoeostasis to rescue httEx1-
mediated toxicity (see Table 1). Figure 2 shows that all
C©The Authors Journal compilation C©2010 Biochemical Society
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Figure 1 Copper increases aggregation of httEx1 in vivo
(A) Representative AFM images (scan size 10 μm× 10 μm) of
recombinant httEx1-Q20 or -Q53 incubated for 24 h in the presence
or absence of 10 μM CuCl2. No signiﬁcant aggregation was seen for
httEx1-Q20, whereas ﬁbrillar structures were evident for the httEx1-Q53
reaction and the number of ﬁbrillar structures per 10 μm2 area increased
in the presence of CuCl2. (B) Dot blot of SDS-insoluble httEx1-Q53
recombinant protein, generated using a ﬁlter trap assay, probed with
the S830 anti-httEx1 antibody. No insoluble material was detected for
httEx1-Q20 (results not shown). Incubation of httEx1-Q53 in the presence
of 10 μM CuCl2 markedly increases the amount of insoluble material at
all time points.
seven copper-binding genes tested provided some degree of
rescue against expanded polyQ toxicity. Because one of the
most effective genes in rescuing toxicity was CRS5, a yeast
homologue of MT, we chose this protein to test its effects on
polyQ aggregation and toxicity in a mammalian cell culture
model of httEx1.
We first established that increased copper concentrations
also increased httEx1 aggregation in vivo and whether
clioquinol, as shown previously [5], was able to reduce
aggregation. Equal expression and transgene integrity of
httEx1-Q25/97 fused to mRFP (monomeric red fluorescent
protein) was verified byWestern blotting (results not shown).
Figure 3(A) shows that, whereas additional copper enhances
aggregation of HttEx1-Q97, clioquinol reduces aggregation
of HttEx1-Q97 in a dose-dependent manner. Copper
similarly increased aggregation in rat phaeochromocytoma
cells (PC12) expressing httEx1-Q97 (results not shown).
Copper did not induce polyQ aggregation of httEx1-Q25
which does not normally aggregate when overexpressed at
similar levels to httEx1 with a polyQ expansion [14,19–22].
Figure 2 Overexpression of genes involved in copper
homoeostasis reduces httEx1 toxicity in yeast
Parental wild-type Y258 yeast containing constructs for overexpression
of the indicated yeast ORFs were transformed with p425-Htt25Q or
p425-Htt103Q and cellular viability determined using growth assays
[16]. The expression of both the htt constructs and the indicated yeast
ORFs is induced by galactose. Five-fold serial dilutions of stationary
phase cultures starting with an equal number of cells of representative
suppressor genes are shown. Expression of htt-Q103 induces signiﬁcant
toxicity compared with expression of htt-Q25. Overexpression of
copper-homoeostatic genes (see Table 1 for details) shows a signiﬁcant
rescue effect towards htt-Q103 toxicity (Cox23 and Ccc2 not shown).
This growth assay was performed twice with identical results.
Clioquinol reduced httEx1 toxicity and copper increased
toxicity in both httEx1-Q25- and -Q97-expressing cells
(at the concentrations of 10 and 100 μM tested) (results
not shown). We next overexpressed human MT3 DNA
for 24 h before infection with the httEx1 adenoviruses.
We chose MT3 because, in contrast with other MT
isoforms, it is mainly expressed in the CNS and is
therefore likely to be the most relevant isoform for
potentially modulating HD phenotypes. As seen in Fig-
ure 3(B), httEx1-Q97 induced significant toxicity compared
with httEx1-Q25, reducing MTS activity by approx. 25%
after 48 h of expression. Notably, co-expression of MT3
was protective, and restored more than 50% of the MTS
activity lost due to httEx1-Q97 toxicity. In parallel with
reduced levels of toxicity, MT3 overexpression signifi-
cantly reduced inclusion body formation (Figure 3C) and
the production of SDS-insoluble material in cells expressing
httEx1-Q97 (Figure 3D).
Discussion
Our results show that altering levels of copper either
by addition of exogenous copper, addition of a copper
chelator or overexpression of copper-homoeostatic genes
affects aggregation and/or toxicity of an aggregation-prone
N-terminal fragment of htt. Copper could participate directly
in HD pathogenesis by increasing aggregation of htt and/or
by altering brain energy metabolism [e.g. LDH (lactose
dehydrogenase) metabolism is altered in mouse HD brain]
C©The Authors Journal compilation C©2010 Biochemical Society
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Figure 3 Copper increases aggregation and HT3 reduces aggregation and toxicity in a mammalian cell model of HD
(A) Percentage of HeLa cells expressing httEx1-Q97mRFP containing an inclusion body (IB) when left untreated or when
treated with clioquinol or CuCl2 (mean± S.E.M.; n = 3). The addition of CuCl2 signiﬁcantly increases the percentage of cells
containing an IB, whereas the presence of clioquinol at a concentration of 10 μM causes a modest decrease in the percentage
of cells containing an IB. (B) MTS absorbance measured at 490 nm for HeLa cells expressing httEx1-Q25/Q97mRFP for 48 h
(mean± S.E.M.; n = 3). Expression of httEx1-Q97 induced toxicity, demonstrated by a 23± 2% reduction in MTS absorbance.
Co-expression of MT3 ameliorated this toxicity by 60± 5%. AU, absorbance units. (C) Percentage of HeLa cells expressing
httEx1-Q97mRFP containing an IB when transfected with an empty vector or with MT3 (mean± S.E.M.; n = 4). Co-expression
of MT3 signiﬁcantly reduced the percentage of cells containing an IB. MT3 expression was veriﬁed by Western blotting
(results not shown). (D) Dot blot of SDS-insoluble material extracted from HeLa cells expressing httEx1-Q97mRFP protein
using a ﬁlter trap assay, probed with an anti-httEx1 antibody (S830). 1× and 0.5× indicate the relative amount of pellet
loaded. No insoluble material was detected for cells expressing httEx1-Q25 as shown previously [14,22] (results not shown).
Cells co-expressing MT3 produced signiﬁcantly less SDS-insoluble material, compared with empty-vector-transfected control
cells (mean± S.D.; n = 2).
[4]. However, it should be noted that some of the copper-
homoeostatic proteins tested in yeast also regulate iron
metabolism and therefore some htt toxicity-modifying genes
in our analysis may be linked to iron metabolism. Copper
metabolism is highly regulated and, although a chelation
approach with clioquinol and tetrathiomolybdate has been
partly successful in reducing pathology in an HD mouse
model [5,23], a more targeted approach to restore copper
homoeostasis may provide further and more consistent
improvement with fewer side effects, which is particularly
important for long-term treatment.
MTs could provide such a missing link. In our study,
two yeast MT homologues, Crs5 and Cup1-2, suppress
toxicity in a yeast model of mutant htt toxicity, with Crs5
showing the most significant rescue of the genes tested. In
addition, one of the mammalian homologues of this yeast
gene, MT3, was also protective against htt toxicity in HeLa
cells. MTs are a family of low-molecular-mass cysteine-rich
proteins which bind not only copper, but also zinc and heavy
metals [24]. MTs are believed to have antioxidant properties
due to their multiple thiol groups, which interact with
ROS. Previous studies have shown that MT3 overexpression
protects against H2O2-induced oxidative stress [25]. Under
stress conditions, including oxidative stress, MTF-1 (metal-
responsive transcription factor 1) activates expression of
MTs via MREs (metal-response elements) present in their
promoter regions. In support of a neuroprotective effect of
MTs, addition of Zn(II) to cultured neurons causes an up-
regulation of MTs and a correlated increase in survival of
dopaminergic neurons [26]. In addition, the neuroprotective
drug resveratrol (neuroprotective in HD models [27]) was
also shown to up-regulate MTs [28]. How MT3 protects
against polyQ toxicity is not clear, but it is likely to be
linked to either the copper-binding ability of this protein
or its general antioxidant actions, or both. Indeed, we have
shown previously that expression of a mutant htt fragment
is associated with an increase in cellular ROS production in
both yeast and mammalian cells [20,29], but it is unknown
how increased ROS are produced. Copper could be involved
inROSproduction bymodulating httEx1 aggregation and/or
C©The Authors Journal compilation C©2010 Biochemical Society
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participate directly in Fenton-type reactions, leading to
biomolecular damage due to oxidative stress. Therefore
the metal-binding and antioxidant properties of MTs make
these proteins good candidates for therapeutically targeting
HD, especially given the importance of oxidative stress inHD
(reviewed in [2,30]) and the likely importance of copper
in htt aggregation/toxicity as shown in this work and in
experiments performed by Fox et al. [4]. This critical study
showed that copper binds to His82 and His98 in a 171-amino-
acid N-terminal fragment of htt. It is therefore possible that
direct interactions of copper with httEx1 (which contains
His82) may affect the oligomerization properties of this
protein and subsequent fibril formation and thereby impact
on the production of toxic intermediate protein species. This
hypothesis remains to be tested in the future using copper-
binding-deficient htt fragments.
In summary, we have shown that copper increases polyQ
aggregation in vitro and in vivo and that overexpression
of MTs protects against polyQ toxicity in two cellular
HD model systems. Given the importance of MTs in
Alzheimer’s disease [31–35] and other chronic CNS diseases
such as amyotrophic lateral sclerosis [36,37] and Parkinson’s
disease [38–43], we propose that MTs are excellent candidate
therapeutic targets for HD.
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